glp 1 medication providers Market Overview: GLP-1 Agonists and the Obesity Market | Blog Insights from Specialty Physicians on

While Lilly and Novo dominate today's $50B+ obesity market, Pfizer is preparing a killer portfolio to steal the spotlight in 2030s

Semaglutide & Sleep Apnea Semaglutide was originally developed to treat type 2 diabetes, a disease that commonly afflicts those suffering from obesity

Given the increasing diversity in treatment paradigm, investors need to carefully think about patient segmentation and archetypes

Any licensed health care providerincluding primary care physicians, nurse practitioners, physician assistants, and specialists such as endocrinologists, cardiologists, and gastroenterologistscan prescribe GLP-1 medications

Non-scale victories (NSVs) can highlight progress that weight alone might not show